357 results about "Hyperplasia" patented technology

The invention discloses a subcutaneous injection site detection and recommendation system based on an intelligent algorithm, and aims to improve the safety of long-term subcutaneous injection and the drug absorption efficiency and reduce the risk of related complications such as subcutaneous hemorrhage, subcutaneous induration and subcutaneous fat hyperplasia at the same time. Comprising a subcutaneous tissue detection module for acquiring subcutaneous vascular distribution, fat layer thickness and induration state of a target part through infrared imaging and ultrasonic technologies and generating subcutaneous tissue characteristic data; the data processing module analyzes the feature data by using an image recognition algorithm, and recognizes a blood vessel dense region, induration and a part where fat hyperplasia has occurred; the injection part recommendation module is used for evaluating an analysis result of the data processing module based on a machine learning algorithm in combination with personalized injection historical data of the patient, and generating an optimal injection part recommendation scheme avoiding a risk area; the intelligent imaging and data analysis technology is utilized, the subcutaneous injection part selection accuracy is improved, and the patient comfort and the treatment effect are improved.

The invention relates to the technical field of medical care, and provides a patient risk dynamic assessment system in medical care teaching, which comprises a data acquisition module used for acquiring multi-modal image data of a postoperative gastric organ anastomosis area of a patient; the data processing module is used for preprocessing the multi-modal image data, establishing a three-dimensional model of organs around the anastomotic stoma and analyzing edge features of the anastomotic stoma; and the risk assessment module is used for constructing an anastomotic stoma state assessment model and outputting comprehensive scores of an anastomotic stoma blood perfusion condition, a tissue metabolism abnormal probability, an anastomotic stoma leakage risk, anastomotic stoma scar hyperplasia and healing trend prediction. A quantum dot fluorescence image, a Raman spectrum image, a CT image and an intraoperative high-definition white light image are enhanced through the system and evaluated, a nursing scheme is obtained in combination with opinions of medical staff, and compared with manual evaluation of the medical staff, the accuracy is higher, the feasibility of the nursing scheme is higher, and medical nursing use is facilitated.

The invention discloses a medical sodium hyaluronate skin repair gel and a preparation method thereof, and mainly relates to the technical field of hyaluronic acid, the medical sodium hyaluronate skin repair gel comprises the following components: sodium hyaluronate, a synergist, glycerol, carbomer, 1, 3-butanediol, triethanolamine and water. Compared with the prior art, the medical sodium hyaluronate skin repair gel prepared by the invention can relieve erythema, pruritus and other symptoms caused by skin inflammation; the wound dressing can also be used for nursing non-chronic wounds, such as superficial wounds, sutured wounds after operations, mechanical wounds and the like; meanwhile, a bacteriostatic environment for wound healing is kept, and skin repair is accelerated; the scar hyperplasia phenomenon in the skin wound repairing process is reduced.

The invention discloses a method for promoting skeletal muscle development and application, and belongs to the technical field of biology. The invention provides a method for promoting skeletal muscle development, an AMPK / p38MAPK pathway is regulated and controlled by activating PPARalpha, the way of activating the PPARalpha is to give a PPARalpha agonist GW7647, and the regulation and control of the AMPK / p38MAPK pathway is shown as reduction of AMPK and P38 phosphorylation levels. Experiments show that the expression of MyoD, MyoG and Pax7 in skeletal muscle can be remarkably improved by activating PPARalpha, the phosphorylation level of AMPK and P38 is inhibited, and therefore muscle fiber proliferation and myoblast proliferation are promoted. The technology can be applied to livestock breeding to improve meat yield or develop drugs for treating skeletal muscle atrophy, and has remarkable economic and clinical values.

This invention relates to a non-invasive predictive kit and method for the progression of benign prostatic hyperplasia (BPH) based on prostatic fluid. The invention provides the application of FGF9 as a non-invasive predictive biomarker for the progression of BPH based on prostatic fluid, wherein the concentration of FGF9 in prostatic fluid serves as an indicator of BPH progression. The invention also provides a method for detecting the concentration of FGF9 in prostatic fluid for non-disease diagnostic purposes. Compared with existing technologies, the non-invasive BPH detection method based on prostatic fluid of this invention has advantages such as non-invasiveness, accuracy, simplicity, practicality, and scalability, and is expected to be widely used in the clinical diagnosis and treatment of prostate diseases.

The utility model discloses an intracavity negative pressure device for treating upper digestive tract fistula, which comprises a drainage catheter, and two ends of the drainage catheter are respectively a suction end and a negative pressure end connected with the negative pressure device; a liquid suction hole adjacent to the suction end is formed in the side wall of the drainage catheter, and a sponge body wrapping the liquid suction hole is arranged on the outer wall of the drainage catheter. The sponge body comprises a first sponge body and a second sponge body with the aperture larger than that of the first sponge body, the first sponge body wraps the suction end, and the second sponge body is arranged between the first sponge body and the negative pressure end. The two cavernous bodies with different pore diameters are arranged in a partitioned mode, the first cavernous body with the small pore diameter absorbs effusion at the wound of the upper digestive tract fistula in time, granulation tissue hyperplasia is promoted, recovery of a patient is facilitated, and the treatment period is shortened; the second sponge body with the large hole diameter enables secretions with large viscidity to be adsorbed in time, the sponge body and the drainage catheter are not prone to being blocked, the service life of the negative pressure device is prolonged, and the replacement frequency of the device is reduced.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for relieving pain, promoting blood circulation, diminishing swelling and removing blood stasis, application thereof and a blood stasis dispersing and pain relieving patch. The invention provides a traditional Chinese medicine composition for relieving pain, activating blood, diminishing swelling and removing stasis. The traditional Chinese medicine composition comprises the following components: lycopodium clavatum, radix clematidis, asarum, gentiana macrophylla, radix angelicae, rheum officinale, notopterygium root, roasted herba epimedii, radix achyranthis bidentatae, peach kernel, radix angelicae pubescentis, vinegar-processed rhizoma corydalis, vinegar-processed rhizoma cyperi, moutan bark, prepared kusnezoff monkshood root, prepared monkshood, vinegar-processed frankincense, Sinkiang lithospermum, vinegar-processed myrrh and sanguisorba officinalis. The blood stasis dispersing and pain relieving patch has the advantages of being good in curative effect, quick in effect taking, convenient to use, safe and reliable, can be used for treating traumatic injuries and pain caused by cervical spondylosis, scapulohumeral periarthritis, lumbar disc herniation, lumbar vertebrae hyperosteogeny, spinal stenosis, sciatica, ankylosing spondylitis, arthritis and other diseases, and can achieve the effect of treating both symptoms and root causes.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis / marijuana, nicotine, and activities including gambling.Compounds are of general formulawith substituents as defined herein.

The present invention discloses a polypeptide combination wound healing preparation with high permeability, specifically relating to a polypeptide combination of tripeptide-1, hexapeptide-9, and palmitoyl-modified peptide, and a new use for treating skin diseases such as wounds, ulcers, burns, scars, and keloids. While the polypeptide combination plays a significant synergistic effect in wound healing, it can effectively prevent and inhibit scar hyperplasia. In addition, the polypeptide combination wound healing preparation of the present invention utilizes the wound healing promoting activity of the composite polypeptide, and is compounded with specific penetration enhancers and antioxidants to be prepared into a gel with functions of moisturizing, promoting healing, reducing infection, and relieving pain, greatly increasing skin penetration, significantly enhancing the skin retention dose, and having significant antibacterial, anti-inflammatory, eschar-removing and muscle-generating, astringent healing, and scar hyperplasia inhibiting effects, being particularly suitable for wound healing and reducing scar residue.

The invention provides novel fusion proteins of Interleukin 15 and prodrugs, and compositions and methods of preparation thereof, useful in treating various diseases and disorders (e.g., hyperplasia, solid tumor or hematopoietic malignancy).

The invention relates to the field of biological dressings, and discloses an artificial dermis dressing as well as a preparation method and application thereof. The preparation method comprises the following steps: adding water into a container, and freezing until the water is frozen; then adding a collagen A solution, freezing and standing; continuing to add collagen B liquid, freezing and standing; continuing to add collagen A liquid, freezing and then freeze-drying; and cross-linking in a glutaraldehyde solution, and cleaning to obtain the artificial dermis dressing. The dressing provided by the invention can provide a good stent effect and promote cell migration and proliferation, and the healing rate is close to 100% after wound making. In the wound healing process, the dressing can inhibit collagen deposition, relieve inflammatory response, inhibit abnormal hyperplasia of blood vessels, inhibit excessive proliferation of fibroblasts and excessive formation of granulation tissues, and effectively prevent scar formation. The dressing can also effectively inhibit abnormal vascular hyperplasia in a wound area, and fibrosis and scar hyperplasia caused by excessive vascular hyperplasia are prevented.

The invention discloses a curcumin-containing polyurethane hydrogel for promoting healing of scalded wounds. The hydrogel is prepared by a one-step method under the condition of no solvent and no catalyst. The raw materials comprise biodegradable polyester polyol, polyethylene glycol, bio-based diisocyanate, an acidic response chain extender, a zwitterionic chain extender, curcumin, a biodegradable cross-linking agent and a notoginsenoside aqueous solution. The hydrogel disclosed by the invention has the effect of promoting healing of scalded wounds; in a hemostasis stage, the hydrogel can quickly stop bleeding and construct a physical barrier; in the inflammation stage, the quaternary ammonium salt in the hydrogel and the physically loaded curcumin have a synergistic effect to effectively kill bacteria; in wound remodeling and hyperplasia stages, notoginsenoside slowly released by the hydrogel can regulate inflammatory response, improve collagen deposition and promote granulation tissue hyperplasia and neovascularization. The hydrogel has good biocompatibility, controllable degradation performance and multifunctional biological activity, and can be used as an efficient special dressing for scalded wounds.

The invention belongs to the technical field of in-vitro diagnostic reagents, and particularly relates to application of a detection reagent for GDF15 protein in extracellular vesicles in preparation of a prostate cancer diagnosis and / or staging kit. According to the invention, enrichment and proteomics detection are carried out on plasma EVs of patients with prostatic cancer (PCa) and benign prostatic hyperplasia (BPH), and through bioinformatics analysis, a potential EV protein marker GDF15 which can be used for early diagnosis of PCa is screened for the first time. The GDF15 protein is verified in a plurality of groups of new clinical queues by further adopting an immunological technology and a targeted quantitative mass spectrometry technology, and the distinguishing ability of the GDF15 protein to PCa and BPH and the distinguishing ability of the GDF15 protein to different PCa stages are determined. The method is expected to promote noninvasive precise diagnosis of clinical PCa, and has a good application prospect.

A stent is disclosed that is configured to maintain patency of the prostatic urethra despite an enlarged prostate. The stent can include a handle that, in an undeflected position, is disposed outside of the flow path of the stent. When the handle is pulled, the handle can deflect to generally aligned with a central axis of the stent. A capture device is disclosed that includes a tapered tip to navigate a working channel of a delivery device and a hook that can capture the stent handle and be moved into a tube to retain the stent handle to facilitate maneuvering of the stent in and out of the working channel of the delivery device. A loading adapter with a tapered port is disclosed that can be disposed on the delivery device to distribute compressive forces applied by the port on the stent during loading into the working channel.

The invention provides a pharmaceutical composition and application thereof in preparation of a compound preparation, and belongs to the field of medicines. The pharmaceutical composition comprises a potassium ion channel opener, a 5 alpha-reductase inhibitor and a phosphodiesterase 5 inhibitor. The pharmaceutical composition can synergistically promote treatment of androgen dependent diseases or prevention of complications, and by taking the pharmaceutical composition of minoxidil, finasteride and tadalafil as an example, the effects in a benign prostatic hyperplasia rat model and an androgenic alopecia mouse model are verified, which indicates that the minoxidil, finasteride and tadalafil have a synergistic interaction effect, and the pharmaceutical composition can be used for treating the androgen dependent diseases or preventing the complications. Good clinical application prospects are realized.

The invention relates to a balloon catheter for transurethral use, having a proximal region (2) comprising an at least single-lumen catheter shaft (4) with an inflation lumen and an inflatable balloon (5) connected to the distal end of the inflation lumen in a fluid-permeable manner, and a distal region (3) comprising a distal shaft (7) and a distal tip (9). The balloon (5) is coated with a medication and a placement aid (10) is provided at least in the proximal region (2). The placement aid (10) is tubular at least in the region of the balloon (5), and the tubular section has a length at least equal to the length of the balloon (5). The balloon catheter according to the invention allows the conservative treatment of benign prostatic hyperplasia without the use of additional imaging techniques.

Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue are disclosed. A system includes a sustained release solid formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising the sustained release solid formulation to the prostate.

The invention discloses a novel compound and application thereof in preparation of a medicine for treating systemic lupus erythematosus. In-vitro experiments show that the compound provided by the invention can further inhibit the secretion of anti-dsDNA IgG + B cell subtype mediated autoantibody by inhibiting the process that B cells are differentiated into plasmoblasts; in-vivo experiments show that the compound provided by the invention can effectively reduce the content of total IgG and anti-dsDNA-IgG in peripheral blood of a systemic lupus erythematosus model mouse, inhibit splenomegaly and peripheral lymph node hyperplasia of the mouse, slow down urine protein increment of the mouse, inhibit glomerular lesion and renal tubule lesion of the mouse and inhibit IFN-gamma generation of the mouse kidney; differentiation of spleen and peripheral lymph node plasmablasts of mice is inhibited, that is, differentiation and function development (antibody secretion) processes of B cells are directly acted. Therefore, the compound provided by the invention has a prospect of being developed into drugs for treating systemic lupus erythematosus.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

1. Name of the product in this design: Wound Tension Relief Device (M Series 2). 2. Purpose of this design: To reduce the tension on both sides of the wound and prevent the wound from widening or hyperplasia due to excessive skin tension. 3. The key design feature of this product is its shape. 4. The picture or photo that best illustrates the key design points: Design 1 3D diagram 1. 5. The left and right views of Design 1-3 of this design have been shown in the perspective view, so the left and right views of Design 1-3 are omitted. 6. Design 1 is designated as the basic design.

The invention relates to the technical field of medicinal liquor preparation, in particular to medicinal liquor capable of activating blood, regulating internal organs, tonifying kidney and treating osteoarthrosis. The invention discloses medicinal liquor with functions of activating blood, regulating internal organs, tonifying kidney and treating osteoarthropathy. The medicinal liquor is prepared by mixing the following raw materials in parts by weight: 1835 to 2400 parts of safflower, 1300 to 2600 parts of ligusticum wallichii, 1600 to 2200 parts of caulis spatholobi, 2300 to 2800 parts of salvia miltiorrhiza, 2100 to 3250 parts of adenophora stricta, 1100 to 2000 parts of eucommia ulmoides, 1350 to 2000 parts of cornu cervi pantotrichum, 1200 to 2100 parts of poria cocos, 1700 to 2600 parts of lucid ganoderma, 1500 to 2000 parts of starfish and 1250 to 1900 parts of radix angelicae pubescentis. The traditional Chinese medicine formula has the beneficial effects of being scientifically prepared, balanced in nutrition and appropriate in proportion, promoting blood circulation to remove blood stasis, enriching yin and nourishing kidney, dispelling wind and eliminating dampness, activating collaterals and relieving pain, restoring consciousness and strengthening brain, and treating carbuncle poison, cervical vertebra hyperosteogeny, lumbar disc herniation, spinal canal stenosis, knee joint hyperosteogeny, knee joint swelling and pain and the like.

A delivery device for positioning an implantable expander to a target location in a prostatic urethra. An implantable biocompatible expander suitable for implantation into a urinary duct is resiliently deformable from a relaxed radially expanded orientation to a radially contracted orientation suitable for transluminal delivery through the urinary duct. The expander may be configured to exert an outward radial force against a wall of the urinary duct when in-situ within the urinary duct. In particular, the expander is suitable for treatment of benign prostatic hyperplasia and configured for implantation into the prostatic urethra between, and substantially spanning the prostatic urethra between, the bladder neck and external sphincter.

The application discloses application of volatile oil of Citrus aurantium in preparation of a medicine for preventing and treating allergic rhinitis. The application proposes that the volatile oil of Citrus aurantium can significantly reduce the levels of mast cell factors IL-1beta and TNF-alpha, and can also significantly reduce the levels of inflammatory factors IL-13 and IL-4 in mice, reduce inflammatory cell infiltration, and reduce eosinophilic granulocyte increase and gland hyperplasia. The application proposes that the volatile oil of Citrus aurantium has great potential as a medicinal and edible raw material for treating allergic rhinitis. The application also proposes that the volatile oil of Citrus aurantium can significantly improve symptoms such as sneezing, runny nose, and nasal itching of mice caused by allergic rhinitis, and the symptoms seriously affect the life of patients.

The present invention relates to a sustained-release injectable composition containing dutasteride. Compared with the conventional Avodart (registered trademark) taken once a day, even if the dosage of dutasteride is the same as or less than that of Avodart, it is possible to show a sustained release effect of dutasteride for 3 months or more, and a long-term drug-taking effect can be shown by a single injection. In addition, it can show a therapeutic effect on benign prostatic hyperplasia, prostate cancer, and hair loss continuously for 3 months or more. The microparticles contained in the sustained-release injectable composition have a constant average diameter, can regulate the release of the drug, and maintain a constant effective drug concentration, and can reduce the foreign body sensation and pain when administered to patients as an injection.

The invention discloses a traditional Chinese medicine composition for treating lumbar and cervical hyperplasia, and belongs to the technical field of traditional Chinese medicines. 7-13 parts of flos daturae; and 5-11 parts of borneol. The preparation method comprises the following steps: pretreating asarum, flos daturae and borneol for later use; putting white spirit into a clean medicine tank; respectively and simultaneously soaking asarum, flos daturae and borneol in the wine for 15-30 days to obtain liquid medicine; the use amount of the white spirit to the total amount of the medicinal materials is (1000-1500ml): (240-360g); after the medicinal materials are soaked, filtering out medicinal liquor; the medicinal liquor is stored in a glass medicine bottle and needs to be stored in a dark place. The traditional Chinese medicine composition for treating lumbar and cervical hyperplasia provided by the invention is mainly used for conditioning and treating lumbar hyperplasia, cervical hyperplasia, scapulohumeral periarthritis, rheumatic arthritis, joint hydrops, long bony spur of joints and long bony spur of posterior roots of feet, and the cure rate reaches 95%.

The invention provides application of paeoniflorin in preparation of a medicine for inhibiting diabetic retinal vascular hyperplasia. The active ingredients of the medicine are one or more of paeoniflorin, a hydrate of paeoniflorin, pharmaceutically acceptable salt of paeoniflorin, a tautomer of paeoniflorin, a stereoisomer of paeoniflorin and a precursor compound of paeoniflorin. Paeoniflorin has potential to be developed into drugs, health care products or functional food for treating diabetic retinopathy.

To provide a skin-whitening agent, autophagy derivative, and epidermis hyperplasia inhibitor.SOLUTION: Provided are a humus extract containing fulvic acid and mineral, and / or a skin-whitening agent including uncoupler other than fulvic acid, an autophagy derivative including uncoupler in keratinocyte, and an epidermis hyperplasia inhibitor including uncoupler.SELECTED DRAWING: None